Medistem Announces Discovery of Novel Stem Cell Population in
Menstrual Blood: Endometrial Regenerative Cells (ERC)
Thursday November 15, 9:29 am ET
Cells Produce 100,000 Times the Number of Growth Factors Found in
Cord Blood
SCOTTSDALE, AZ--(MARKET WIRE)--Nov 15, 2007 -- Medistem Laboratories,
Inc. (OTC BB:MDSM.OB - News) (Frankfurt:S2U.
collaboration with researchers from the University of Western
Ontario, University of Alberta, and the Bio-Communications Research
Institute, has published a paper describing a novel stem cell
population derived from menstrual blood. The publication,
entitled "Endometrial Regenerative Cells: A Novel Stem Cell
Population" appeared in today's Journal of Translational Medicine and
is freely available at http://www.translat
medicine.com/
"I view the discovery of the Endometrial Regenerative Cell (ERC) as a
great step forward in providing an ethical, easily accessible, and
potentially highly useful adult stem cell for treatment of numerous
degenerative conditions," said Dr. Xiaolong Meng, head of the
research team. He continued, "ERC cells can be converted into
basically all the major tissues of the body, including the liver,
lung, pancreas, brain, heart, blood vessel, and muscle. Additionally,
these cells produce 100,000 times the number of growth factors found
in cord blood, opening the door to numerous regenerative
applications.
This is the first publication in a peer-reviewed medical journal
demonstrating that stem cells from the menstrual blood can generate
numerous tissues and possess unique molecular and cellular
characteristics.
"The ability to take a cell and differentiate it into the tissue type
needed by the body creates a world of opportunity in the world of
organ and tissue regeneration,
CEO of Medistem. He added, "With IP filed around the cell line, we
have begun taking the next steps in the commercialization process.
Currently, our collaborators at Western Ontario, Alberta, and the Bio-
Communications Research Institute are doing a series of pre-clinical
studies to establish efficacy data in a variety of indications. The
indications currently being assessed include diabetes, liver
cirrhosis, lung fibrosis, organ rejection, and multiple sclerosis.
Should the data gathered prove strong in one or all the indications
the next step will be to file INDs with the FDA and move into
clinical trials," said Riordan.
About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers,
develops, and commercializes adult stem cell products that address
serious medical conditions. While drug discovery and development is
its primary focus, Medistem has compiled a body of proprietary
technologies it outlicenses to commercial entities in markets where
stem cell administration is permissible. Due to its licensee
relationships and collaborative efforts with respected institutions,
Medistem believes it is well positioned to be a leading developer of
adult stem cell products.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation
of an offer to buy any of our securities. This document contains
certain forward-looking statements within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking
statements may include projections of matters that affect revenue,
the ability to develop or license certain technologies; operating
expenses or net earnings; projections of capital expenditures;
projections of growth; hiring plans; plans for future operations;
financing needs or plans; plans relating to the company's products
and services; and assumptions relating to the foregoing.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Future events and actual results could differ materially from those
set forth in, contemplated by, or underlying the forward-looking
information.
Some of the important factors that could cause the company's actual
results to differ materially from those projected in forward-looking
statements made by the company include, but are not limited to, the
following: technology development limitations, intense competition,
risk of business interruption, management of rapid growth, need for
additional financing, regulatory approvals and requirements,
dependence on key personnel and research, management and other
administrative costs.
These factors are discussed in greater detail in the company's
quarterly and annual periodic reports, all as filed with the
Securities and Exchange Commission.
Contact:
Contact:
Medistem Laboratories, Inc.
Chris McGuinn
602-318-3535
http://www.medistem
Source: Medistem Laboratories
http://biz.yahoo.
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
